Cytomegalovirus viral load at initiation of pre‐emptive antiviral therapy impacts cytomegalovirus dynamics in pediatric allogeneic hematopoietic cell transplantation recipients

Abstract

AbstractBackgroundCytomegalovirus (CMV) contributes to morbidity and mortality in allogeneic hematopoietic cell transplantation (allo‐HCT) recipients. Pre‐emptive antiviral therapy (PET) reduces the incidence of CMV end‐organ disease (EOD), though relevant viral thresholds to initiate PET remain undefined. We evaluated the impact of viral loads (VLs) at PET initiation on virologic and clinical outcomes following pediatric allo‐HCT.MethodsSingle‐center retrospective cohort analysis of children who underwent their first allo‐HCT from January 2014 to December 2020. Weekly quantitative plasma CMV polymerase chain reaction was performed until Day +100 and PET was initiated once VL exceeded a pre‐defined threshold per institutional guidelines. Patients were followed for 1‐year post‐HCT to evaluate virologic and clinical outcomes including end‐organ disease (EOD), overall survival (OS), and non‐relapse mortality (NRM).ResultsAmong 146 allo‐HCT recipients, CMV DNAemia occurred in 40 patients (27%) at a median of 15 days post‐HCT (interquartile range 6–28.5). Ten percent (n = 4) had spontaneous resolution of DNAemia, while 90% (n = 36) required PET. PET initiated when CMV VL was ≥ 1000 IU/mL (n = 21) vs when VL < 1000 IU/mL (n = 15) resulted in higher peak CMV VL (12,670 vs. 1284 IU/mL, p = 0.0001) and longer time to CMV DNAemia resolution (36 vs. 24 days, p = 0.035). There were no differences in EOD, OS, or NRM at 12 months post‐HCT based on VL at PET initiation.ConclusionsInitiating PET when CMV VL was ≥1000 IU/mL resulted in significantly higher peak VL and prolonged DNAemia, with no differences in EOD, OS, or NRM at 12 months post pediatric HCT. image